• HBsAg Exploits TBK1 to Suppress IFN-I and Induce Early Autop

  2026-05-03

  This study uncovers a unique mechanism by which hepatitis B surface antigen (HBsAg) hijacks the kinase TBK1 to suppress type I interferon (IFN-I) responses and induce an early, incomplete autophagy state in hepatocytes. These insights refine our understanding of HBV immune evasion and provide new mechanistic connections between innate immunity and autophagy.

• Protease Inhibitor Cocktail: Redefining Protein Stability in

  2026-05-02

  Explore how the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) uniquely safeguards plant protein integrity, illuminating the interplay between protease inhibition and RNA-based plant immunity. Gain practical insights for advanced molecular assays with this comprehensive analysis.

• Trelagliptin Promotes Osteoblastic Differentiation via RUNX2

  2026-05-02

  This study demonstrates that Trelagliptin, a DPP-4 inhibitor, enhances osteoblastic differentiation in MC3T3-E1 cells by upregulating RUNX2 through an AMPK-dependent pathway. These findings suggest a promising new therapeutic avenue for osteoporosis and inform protocols requiring precise nucleated cell isolation in bone research.

• Lymphodepleting Chemotherapy Enhances T Cell Therapy via Ant

  2026-05-01

  This study demonstrates that lymphodepleting chemotherapy, notably cyclophosphamide and fludarabine, remodels the tumor antigenic landscape and upregulates antigen presentation machinery. The result is a significant improvement in the efficacy of neoantigen-directed adoptive T cell therapy, offering a mechanistic foundation for optimizing immunotherapy regimens in solid tumors.

• Fucoidan: Mechanistic Insights and Translational Strategies

  2026-04-30

  This thought-leadership article dissects the mechanistic basis and translational potential of Fucoidan, a sulfated α-L-fucan, as an anticancer and immune-modulating agent. By integrating recent evidence on caveolin-1 targeting in breast cancer and providing workflow-anchored protocol recommendations, it offers strategic guidance for researchers seeking to leverage high-purity Fucoidan—such as APExBIO’s C4038—in advanced oncology and immunology pipelines.

• Doxorubicin in 3D Cancer Models: Applied Workflows & Optimiz

  2026-04-30

  Doxorubicin (Adriamycin) remains the gold-standard chemotherapeutic agent for dissecting cancer cell death and drug resistance, especially within advanced 3D in vitro models. Explore optimized protocols, troubleshooting guidance, and actionable insights that ensure robust, reproducible results across cancer research applications.

• Stiripentol: Advanced LDH Inhibitor Workflows for Epilepsy a

  2026-04-29

  Stiripentol stands out as a noncompetitive LDH inhibitor, enabling precise modulation of lactate metabolism for both neuroscience and oncology research. This guide details applied workflows, troubleshooting insights, and protocol enhancements that maximize Stiripentol’s utility in dissecting the astrocyte-neuron lactate shuttle and tumor microenvironment.

• PFOS Induces Ferroptosis and ER Stress in Human Kidney Cells

  2026-04-29

  This study provides new mechanistic insights into how perfluorooctane sulfonate (PFOS) causes injury in human proximal tubular epithelial (HK-2) cells via ferroptosis and endoplasmic reticulum (ER) stress pathways. These findings clarify molecular events underlying PFOS nephrotoxicity, informing future research on environmental toxicants and kidney disease.

• Puromycin dihydrochloride: Technical Guidance for Cell Selec

  2026-04-28

  Puromycin dihydrochloride is used for precise selection and maintenance of eukaryotic and prokaryotic cell lines expressing the pac gene, and for probing translation and ribosome function. Its use is optimal in workflows requiring stringent protein synthesis inhibition or selection marker application, but must be carefully titrated to each cell type to avoid nonspecific cytotoxicity.

• Decoding Protein Dynamics: The Science of Triple Color Prest

  2026-04-28

  Explore how the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) transforms SDS-PAGE and Western blot workflows. This article delves into its scientific design, advanced compatibility, and unique benefits for phosphoprotein and fluorescent imaging assays.

• Neurotensin: Precision Neurotensin Receptor 1 Activator Work

  2026-04-27

  Neurotensin (CAS 39379-15-2) empowers advanced investigations into GPCR trafficking and miRNA regulation, overcoming workflow bottlenecks tied to spectral interference and reproducibility. APExBIO’s high-purity peptide delivers reliable, interference-resistant results in both fluorescence-based and conventional assays, making it indispensable for cutting-edge gastrointestinal physiology research.

• Raising the Bar: Cap 1 Luciferase mRNA for Translational Sci

  2026-04-27

  Explore how EZ Cap™ Firefly Luciferase mRNA, featuring Cap 1 structure and an optimized poly(A) tail, is driving a paradigm shift in translational assay design. This thought-leadership article blends mechanistic insights with real-world workflow guidance, benchmarking against current literature on mRNA stability, delivery, and in vivo efficacy. Discover how APExBIO’s innovation helps researchers overcome bioluminescent assay challenges, bridge in vitro and in vivo gaps, and set new standards in molecular biology.

• HBTU in Advanced Peptide Synthesis: Workflow, Troubleshootin

  2026-04-26

  HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) delivers reproducible, racemization-resistant peptide bond formation for demanding synthetic applications. Learn how this APExBIO reagent empowers high-yield, selective workflows and enables next-generation peptide therapeutics, as exemplified by dual enzyme-responsive cancer-selective peptide assemblies.

• Gamithromycin (BA1074): Mechanism, Evidence, and Veterinary

  2026-04-25

  Gamithromycin (ML-1709460) is a semi-synthetic macrolide antibiotic with documented broad-spectrum efficacy against respiratory pathogens in veterinary species. Its mechanism—targeting bacterial protein synthesis via the 50S ribosomal subunit—enables potent, concentration-dependent activity. Dose optimization is driven by PK/PD indices, notably AUC24h/MIC, supporting its application in the treatment of bovine respiratory disease and Glässer’s disease in pigs.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody: Signal Amplification

  2026-04-24

  Uncover new scientific insights into the Cy5 Goat Anti-Mouse IgG (H+L) Antibody, a Cy5-conjugated secondary antibody from APExBIO. This article reveals how advanced signal amplification strategies transform mouse IgG detection across immunoassays, with unique practical guidance and evidence-backed protocol insights.

444 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page